January 24, 2018
Ablynx opens door for new scientific boss
Belgian based drugmaker Ablynx has appointed Robert Friesen, PhD, as Chief Scientific Officer (CSO), who will begin his role in…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
January 24, 2018
ImmuPharma cashes in £10M ($14.03M)
ImmuPharma has completed a fundraise totalling £10 million (14.03million) before expenses by placing 6,944,445 new ordinary shares of 10p each…
January 23, 2018
Portola Pharmaceuticals to present late-breaker abstract on antidote for deadly bleeding patients
Portola Pharmaceuticals said that it will present an abstract about results from its trial in Phase 3b/4 of its investigational…
January 23, 2018
ProcureCon Pharma explains Analytical and Digital Procurement in Pharma
Join ProcureCon Pharma to learn how to master Analytical and Digital Procurement in Pharma. Download agenda here: https://procureconhealthcare.wbresearch.com
January 23, 2018
U.S. FDA OK’s Baxter’s ready-to-use cardiovascular medication Bivalirudin
Baxter International has announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection…
January 23, 2018
Amgen’s and Novartis’s Aimovig reduces migraine days for people who failed to be rescued with earlier treatments, study shows
Amgen’s Phase 3b study called Liberty, in co-development with Novartis, aimed to test Aimovig for treating migraine, has met it’s…
January 23, 2018
Alexion Pharmaceuticals refreshes its board of directors
Alexion Pharmaceuticals has welcomed Deborah Dunsire, M.D. as the company’s Board of Directors new independent director.
January 23, 2018
Arena Pharmaceuticals to host talks about treatment of autoimmune diseases
Arena Pharmaceuticals ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused on sphingosine-1-phosphate…
January 22, 2018
Novartis buys French radiopharmaceutical company AAA for $3.9 billion
Novartis Group France has completed a tender to buy Advanced Accelerator Applications S.A. for $3,9 billion, or $41.00 per ordinary…
January 22, 2018
Silence Therapeutics nets important patent in Europe
Silence Therapeutics strengthen the protection for its innovative chemical modification technology in Europe, as the European Patent Office granted it…